Profound Medical (NASDAQ: PROF; TSX: PRN) has announced the introduction of its latest Treatment Delivery Console (TDC) software being deployed across Profound’s TULSA-PRO-installed base.
According to Profound, the TDC software further builds upon previously implemented TULSA-AI modules focused on increasing procedural efficiency and physician experience, while reducing planning complexity. It brings two new focuses of features that are designed to even further increase TULSA Procedure efficiency and support the ability to regionally ablate tissue for a variety of prostate indications:
- Real-time iMRI control, putting the surgeon more squarely in the driver’s seat of TULSA-PRO’s supervised robotic autonomy.
- Physician-requested improvements to the user interface and hardware control.
In a statement, Arun Menawat, CEO and chairman of Profound, commented, “Today, a few TULSA physicians already report being able to perform up to four TULSA Procedures per day. Many TULSA physicians also report that TULSA-PRO is already one of the least stressful devices they use. The objective of introducing the latest TDC software is to further increase ease of use and reduce overall procedure times, and provide what we believe is a roadmap that would allow surgeons to achieve up to six procedures per day.”
Mr. Menawat added, “TULSA is the only prostate treatment modality that deploys supervised robotic autonomy, meaning it executes predefined and/or AI-driven tasks independently. This compares to competitive robotic systems that instead rely on direct, real-time human hand movement and control. Putting physicians more squarely in the driver’s seat of TULSA-PRO’s autonomous robotics via this software upgrade will further enhance their ability to deliver consistent, highly personalized prostate ablation based on each patient’s unique anatomy and disease. In the future, it may also give us an even stronger competitive advantage as prostate surgery advances to its next potential frontier, including incisionless telesurgery.”
